India, March 24 -- he Drugs Controller of India has intensified regulatory surveillance against unauthorized sale and promotion of GLP-1 based Weight Loss Drugs. The move comes amid growing concerns over the increasing availability of multiple generic variants of these drugs in the Indian market, through retail pharmacies, online platforms, wholesalers, and wellness clinics.

The Ministry of Health and Family Welfare said that these drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks. Taking cognisance of the situation, India's Drugs Controller, in collaboration with State Regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceut...